Related Experiment Video

Updated: Mar 18, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer

Alessandra Modena1, Roberto Iacovelli2, Aldo Scarpa3

  • 1Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata (AOUI), University of Verona, Piazzale L.A. Scuro, 10, 37134, Verona, Italy.

Targeted Oncology
|July 13, 2016
PubMed

Insights

Germline BRCA mutations are key risk factors for aggressive prostate cancer. Targeting synthetic lethality with agents like PARP inhibitors offers new therapeutic avenues for metastatic castration-resistant prostate cancer (mCRPC).

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) presents significant challenges due to its heterogeneity and lethal course.
  • Germline BRCA mutations are strongly linked to aggressive prostate cancer phenotypes and poorer clinical outcomes.

Purpose of the Study:

  • To review the role of BRCA mutations in prostate cancer.
  • To discuss the clinical implications of BRCA aberrations in mCRPC management.
  • To highlight the potential of synthetic lethality strategies in prostate cancer therapy.

Main Methods:

  • Literature review of studies on BRCA mutations in prostate cancer.
  • Analysis of genomic data and clinical outcomes.
  • Discussion of therapeutic strategies targeting synthetic lethality.

Main Results:

  • Germline BRCA mutations are significant risk factors for aggressive prostate cancer.
  • Synthetic lethality, particularly with poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPi) and platinum compounds, shows therapeutic promise.
  • Understanding treatment resistance mechanisms is crucial for optimizing personalized medicine.

Conclusions:

  • BRCA mutations impact prostate cancer aggressiveness and outcomes.
  • Targeting synthetic lethality offers a promising avenue for mCRPC treatment.
  • Further research into biomarkers and resistance mechanisms is essential for advancing personalized prostate cancer care.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.7K

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.4K